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Recently published health improvement targets for
England aim to reduce adult smoking rates (from 26%
in 2002) to 21% or less by 2010, reducing prevalence
among routine and manual socioeconomic groups
(from 31%) to 26% or less.1 I estimate the contribution
of current UK NHS smoking cessation services to
delivery of these targets.
Participants, methods, and results
I took local smoking cessation data from quarterly
returns, population estimates from 2001 census
figures, and smoking prevalence estimates from the
general household survey.
Northumberland and Tyne and Wear has 1.135
million people aged 15 and above (543 000 men,
592 000 women), of whom 333 000 are assumed to be
smokers (33% of men and 26% of women, applying the
general household survey prevalences for the north
east aged at least 16 to the at least 15 population).
In 2003-4, 20 103 people in the region used smok-
ing cessation services, of whom 9910 had still quit after
four weeks (49.3%).Of these, I estimated 35-40% would
still have quit after a year,2 a long term figure of 3500-
4000.
I assumed that the background quit rate was 1.5%
(5000 a year).3 If all long term quitters using the
services were additional to this, they would represent
an annual attributable fall in local prevalence of
0.31-0.35%. Given that some of the quitters using the
services would have quit without intervention, the true
figure is smaller.
Numbers needed to treat (NNTs) offer an
alternative approach to calculating attributable reduc-
tion in prevalence. For each additional quitter at one
year, NNTs are around 17 for nicotine replacement
treatment (gum or patches in large trials) and eight for
bupropion.4 For entrants to the services whose
treatment was recorded, 91% received nicotine
replacement and 6% bupropion. An assumed average
NNT of 15 would yield 1350 additional quitters, an
annual attributable prevalence fall of 0.12%.
Comment
Although local NHS smoking cessation services had
the highest throughput in the country, a fall in
prevalence of more than 0.1-0.3% above background
in 2003-4 was unlikely. At current rates the services
would be unlikely to reduce prevalence in the region
by more than 0.8-2.4% by 2010.
National smoking prevalence in the 1990s pla-
teaued, but may have fallen by 0.4% a year in
1999-2002. We cannot assume that the contribution of
NHS services will be entirely additional to this trend,
given that some services were active during 1999-2002.
In the north east, much of the population is
“routine and manual” and lies within the “fifth of areas
with the worst health and deprivation indicators” for
whom narrowing of the circulatory disease and cancer
inequality gaps are also targets. Passive smoking is
worse in the north of England than in the south, and
local prevalence of women smoking throughout preg-
nancy is about 25%.
Against this background, it is disturbing that the
new English smoking prevalence targets do not
propose a narrowing of the inequalities gap. As they
stand, the gap in smoking prevalence would widen
from 19% (31/26 − 1) to 24% (26/21 − 1). The likely
impact of this on health disadvantage would be greater
still.
In 1988-95 Californian smoking prevalence fell
10% against a background fall of 5.5% in the rest of the
United States. Crucially, California used broader legis-
lative action to achieve this, since “heavy early
investment in cessation services had produced
disappointing results.”5
To narrow health gaps in England it is not sufficient
simply to be better at delivering smoking cessation.
Bupropion and nicotine replacement are among the
most cost effective of all healthcare interventions, but
comprehensive restriction of smoking in all workplaces
works better. Both are needed and deprived areas need
more of both.
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What is already known on this topic
California’s tobacco control programme initially
focused on smoking cessation with disappointing
results
What this study adds
At best, current NHS smoking cessation services
are unlikely to be reducing the prevalence of
smoking by more than 0.1-0.3% a year
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